Normunity develops precision immuno-oncology therapies that utilize proprietary discovery platforms to identify and target mechanisms of immune disruption in cancer. By creating a new class of immune normalizers, the company aims to enhance the normal immune response, increasing the effectiveness of cancer treatment for more patients.
Funding
$182.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ESFounders
Product
Problem
Current cancer immunotherapies do not work for a significant number of patients, suggesting that there are undiscovered mechanisms that disrupt the normal immune response to cancer. These hidden mechanisms within the complex interactions between human cancer and the immune system remain untapped.
Solution
Normunity is developing precision immuno-oncology therapies designed to target previously unknown mechanisms of immune disruption in cancer. The company utilizes proprietary discovery platforms to identify these novel targets and create a new class of cancer immunotherapies, called immune normalizers. These therapies aim to restore and enhance the normal immune response, thereby increasing the effectiveness of cancer treatment for a broader range of patients. By freeing the immune system to work normally against cancer, Normunity seeks to develop treatments and cures.
Target Audience
The primary target audience includes cancer patients who do not respond to current immunotherapies, as well as the medical professionals treating them, including oncologists and immunologists.
Features
- Proprietary discovery platforms to uncover novel immuno-oncology mechanisms.
- Focus on identifying and targeting points of immune disruption.
- Development of a new class of immune normalizers.
- Aims to enhance the normal immune response to cancer.
- Collaborative approach integrating expertise from scientific discovery and drug development.